Xie Wenting, Kong Xue, Zheng Hailin, Mei Huan, Ge Naicen, Liu Weida, Liang Guanzhao, Li Xiaofang
Department of Medical Mycology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
Microbiol Spectr. 2025 Aug 5;13(8):e0061825. doi: 10.1128/spectrum.00618-25. Epub 2025 Jun 23.
The worldwide emergence of has garnered significant attention due to its growing resistance to conventional antifungal therapies, posing significant challenges to the effective management of dermatophytosis. The activities of 16 antifungals were tested against 37 isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute protocol M38-A3. Luliconazole and amorolfine exhibited low MICs, while itraconazole showed moderately decreased susceptibility, making them preferred treatment options. Echinocandins demonstrated favourable activity against , but their potential as therapeutic alternatives for recalcitrant dermatophytosis remains uncertain due to pharmacokinetic and pharmacodynamic limitations. In contrast, terbinafine, fluconazole, griseofulvin, oteseconazole, isavuconazole, ravuconazole, and amphotericin B exhibited elevated MICs for many strains, with strong correlations between certain azoles, indicating potential cross-resistance. A difference in the susceptibility to terbinafine and voriconazole between Chinese and Indian isolates was observed. These findings could provide valuable insights into antifungal resistance patterns and help guide treatment strategies for infections.
is a novel emerging dermatophyte that has rapidly spread globally in recent years. Its resistance to first-line antifungal agents, particularly terbinafine and fluconazole, has significantly limited treatment options, emphasizing the urgent need for alternative therapies. This study provides comprehensive antifungal susceptibility data for 16 available antifungal agents, offering valuable insights into potential treatment strategies.
由于其对传统抗真菌疗法的耐药性不断增加，近年来在全球范围内出现的[某种真菌]引起了广泛关注，给皮肤癣菌病的有效管理带来了重大挑战。根据临床和实验室标准协会协议M38 - A3，采用肉汤微量稀释法对37株[该真菌]分离株测试了16种抗真菌药物的活性。卢立康唑和阿莫罗芬表现出低最低抑菌浓度（MIC），而伊曲康唑的敏感性略有下降，使其成为首选治疗方案。棘白菌素类药物对[该真菌]显示出良好的活性，但由于药代动力学和药效学限制，它们作为顽固性皮肤癣菌病治疗替代药物的潜力仍不确定。相比之下，特比萘芬、氟康唑、灰黄霉素、奥替康唑、艾沙康唑、雷夫康唑和两性霉素B对许多菌株表现出升高的MIC，某些唑类药物之间存在强相关性，表明可能存在交叉耐药性。观察到中国和印度分离株对特比萘芬和伏立康唑的敏感性存在差异。这些发现可为抗真菌耐药模式提供有价值的见解，并有助于指导[该真菌]感染的治疗策略。
[该真菌]是一种近年来在全球迅速传播的新型皮肤癣菌。它对一线抗真菌药物，特别是特比萘芬和氟康唑的耐药性显著限制了治疗选择，凸显了对替代疗法的迫切需求。本研究提供了16种现有抗真菌药物的全面抗真菌药敏数据，为潜在治疗策略提供了有价值的见解。
